Table 4 Selected prospective studies on radio/chemotherapy in older patients with primary central nervous system lymphoma (PCNSL)
From: Radiation therapy for older patients with brain tumors
Authors | Type of study | Patients | Age years | CHT | RT | Median PFS months | Median OS months |
|---|---|---|---|---|---|---|---|
O’Neill et al. [81] | single arm phase II | 21 | >60 | CHOP and HD-ARAC | 50,4 Gy WB | 6.2, 25% at 1 year | 8, 14% at 2 year |
Fritsch et al. [82] | single arm phase II | 28 | >65 | R-MCP | No RT | 31% at 3 years | 31% at 3 years |
Ghesquières et al. [83] | multicenter phase II | 54 | 61-70 > 70 | age-adapted C5R | 20 Gy WB 30 Gy boost | 61-70, 2% at 5 years >70, 11% at 5 years | 61-70, 31% at 5 years >70, 17% at 5 years |
Hoang-Xuan et al. [84] | multicenter phase II | 50 | >60 | hd-MTX, lomustine, procarbazine, intrathecal MTX and ARA-C | No RT | 40% at 1 year | 14.3 |
Illerhaus G et al. [85] | multicenter phase II | 31 | >65 | hd-MTX, procarbazine, CCNU | 50 Gy WB for not responders | 5.9 | 15.4 (33% at 5 years) |
Laack et al. [86] | multicenter phase II | 19 | >70 | HD-metilprednisolone | 41.4 Gy WB 9 Gy boost | 3.4, 32% at 6 months | 5.5, 37% at 6 months |
Roth P et al. [87] | multicenter phase II (G-PCNSL-SG-1) | 66 | >70 | HD-MTX | +/− RT | 4 (16.1 for complete responders) | 12.5 |